VK2735 vs Tirzepatide

Overview

VK2735 is Viking Therapeutics’ investigational dual GLP-1/GIP receptor agonist in development for obesity, with both injectable and oral formulations. Tirzepatide (Mounjaro, Zepbound) is Eli Lilly’s approved dual agonist.

Key distinction: Tirzepatide is approved with extensive data; VK2735 is in Phase 2 development but has generated significant interest due to promising early results and oral formulation potential.

Key Facts

Aspect	VK2735	Tirzepatide
Developer	Viking Therapeutics	Eli Lilly
Class	GLP-1/GIP dual agonist	GLP-1/GIP dual agonist
FDA Status	Investigational (Phase 2)	Approved
Formulations	Injectable + Oral	Injectable

Mechanism Comparison

Aspect	VK2735	Tirzepatide
GLP-1 Receptor	Agonist	Agonist
GIP Receptor	Agonist	Agonist
Mechanism	Dual activation	Dual activation
Half-life	~6 days	~5 days
Structure	Peptide	Peptide

How They Work

VK2735:

• Dual agonist activating both GLP-1 and GIP receptors
• Similar mechanism to tirzepatide
• Novel peptide sequence with proprietary modifications
• Oral formulation (VK2735 tablets) also in development

Tirzepatide:

• Dual agonist at GLP-1 and GIP receptors
• GIP component enhances metabolic effects
• Single 39-amino acid peptide
• Well-characterized receptor binding profile

Evidence Quality

VK2735 Research

Trial Phase	Status	Key Findings
Phase 1	Completed	Safety and tolerability established
Phase 2 (Injectable)	Completed	~14.7% weight loss at 13 weeks
Phase 2 (Oral)	Ongoing	Early data positive
Phase 3	Not started	Planned

Current evidence:

• Phase 2 showed rapid weight loss (14.7% at 13 weeks)
• Weight loss curve not yet plateaued at trial end
• Oral formulation showing feasibility
• Limited long-term data

Tirzepatide Research

Trial Phase	Status	Key Findings
SURPASS program	Completed	Robust T2D data
SURMOUNT program	Completed	Up to 22% weight loss
Phase 3	Extensive	Multiple indications
Post-marketing	Ongoing	Real-world evidence growing

Established evidence:

• Large randomized controlled trials
• Up to 22% weight loss in SURMOUNT-1
• Superior to semaglutide in comparator trials
• 2+ years of post-approval data

Efficacy Comparison

Weight Loss Results

Metric	VK2735	Tirzepatide
Trial duration	13 weeks (Phase 2)	72 weeks (Phase 3)
Maximum weight loss	~14.7% at 13 weeks	~22.5% at 72 weeks
Rate of loss	Rapid early loss	Steady progression
Plateau reached	No	Yes (by ~72 weeks)

Important context: Direct comparison is difficult due to different trial durations. VK2735’s 13-week results are promising but cannot be directly compared to tirzepatide’s 72-week outcomes.

Projected Potential

Some analysts project VK2735 could achieve similar or greater weight loss than tirzepatide if the Phase 2 trajectory continues, but this remains speculative until Phase 3 data.

Evidence Strength Comparison

Factor	VK2735	Tirzepatide
Peer-reviewed studies	Few	Extensive
Phase 3 trials	None	Multiple completed
Total patients studied	~200	Thousands
Long-term data	None	Available (2+ years)
Overall quality	Low (early stage)	High

Side Effects

VK2735 (Phase 2 Data)

Side Effect	Incidence	Notes
Nausea	~30-40%	Dose-dependent
Vomiting	~15-20%	Common with class
Diarrhea	~10-15%	GI effects expected
Constipation	Reported	—
Discontinuation rate	~10%	Due to GI effects

Tirzepatide (Established Profile)

Side Effect	Incidence	Notes
Nausea	12-33%	Improves with time
Diarrhea	12-21%	Usually transient
Vomiting	5-12%	Dose-related
Constipation	6-12%	Common

Safety Considerations

VK2735:

• Full safety profile not yet characterized
• Phase 2 GI tolerability similar to class
• Oral formulation safety being evaluated
• Long-term effects unknown

Tirzepatide:

• Well-characterized GI side effect profile
• Rare risks include pancreatitis (class effect)
• Thyroid C-cell tumor warning (precautionary)
• Extensive safety database

Oral Formulation Advantage

VK2735 Oral Development

Aspect	Status
Formulation	Tablet in development
Phase	Phase 2 ongoing
Early data	Encouraging absorption
Potential advantage	No injections needed

This could be a significant differentiator if VK2735 oral demonstrates:

• Comparable efficacy to injectable
• Acceptable bioavailability
• Manageable GI tolerability

Comparison to oral semaglutide: Oral GLP-1 agonists have lower bioavailability and require fasting; VK2735 oral formulation details pending.

Regulatory Status

Aspect	VK2735	Tirzepatide
FDA Status	Investigational	Approved
Phase	Phase 2	Post-marketing
Availability	Clinical trials only	Prescription
Projected approval	2026+ (if successful)	Already approved

Development Timeline

VK2735 Path to Market (If Successful)

Milestone	Status/Timeline
Phase 2 completion	Completed (2024-2025)
Phase 3 initiation	Underway (2025)
Phase 3 completion	Expected 2026-2027
FDA submission	Projected 2027+
Potential approval	Projected 2028+

Note: Timelines are estimates and subject to change based on trial results and regulatory interactions. Check current clinical trial registries for latest status.

Market Positioning

Factor	VK2735	Tirzepatide
First-mover advantage	No	Yes
Oral option	In development	No
Differentiation	Efficacy + oral	Established market leader
Competition	Entering crowded market	Current standard

Who Might Consider Each

Tirzepatide (Available Now):

• Patients meeting prescribing criteria
• Type 2 diabetes or chronic weight management
• Those wanting established, approved therapy
• Patients comfortable with weekly injections

VK2735 (Future, If Approved):

• Must await regulatory approval
• May appeal to those preferring oral medication
• Patients who have not responded to current options
• Currently only available via clinical trials

Summary

Factor	VK2735	Tirzepatide
Evidence quality	Low (Phase 2)	High (Phase 3, approved)
Weight loss (reported)	~14.7% (13 weeks)	~22% (72 weeks)
Oral formulation	In development	Not available
Availability	Clinical trials only	Prescription
Safety profile	Limited data	Well-characterized
Market status	Investigational	Approved, available

Key takeaway: Tirzepatide is an approved, well-studied medication available now. VK2735 shows promising early results and potential oral convenience but remains investigational. The compounds cannot be directly compared until VK2735 completes Phase 3 trials.

---

This comparison is for educational purposes only. VK2735 is not FDA-approved and only available in clinical trials. Tirzepatide requires a prescription. Consult a healthcare provider for treatment decisions.